Skip to main content
Erschienen in: Supportive Care in Cancer 5/2011

01.05.2011 | Original Article

Determinants of quality of life in patients with advanced cancer

verfasst von: Camilla Zimmermann, Debika Burman, Nadia Swami, Monika K. Krzyzanowska, Natasha Leighl, Malcolm Moore, Gary Rodin, Ian Tannock

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Improving health-related quality of life (HRQL) is the main goal of palliative care and an important outcome for oncology trials. This study examines medical and sociodemographic determinants of HRQL in outpatients with advanced cancer.

Methods

Patients with metastatic gastrointestinal, genitourinary, breast, lung or gynecological cancer, ECOG 0-2, and clinical prognosis of 6 months to 2 years were recruited from outpatient medical oncology clinics. HRQL was measured using the FACT-G questionnaire and the FACIT-Sp meaning and peace (existential) subscale. The influence of demographic and medical characteristics on HRQL was determined using t tests and analysis of variance, with Tukey’s correction for multiple comparisons. Multivariate linear regression was used to determine independent predictors.

Results

Of 285 patients, 57% were female and the median age was 61 years; 44% were alive at latest follow-up; and of those deceased, the mean survival time was 10 months. The strongest determinants of overall HRQL were increased age (p < 0.001), good performance status (PS; p < 0.001) and survival time >6 months (p = 0.001). Compared to patients receiving cancer treatment, those awaiting new treatment had worse emotional well-being (p < 0.001), while those on surveillance or whose treatment had been stopped had worse existential well-being (p = 0.03). Male gender predicted better emotional and physical well-being and lower income predicted worse social well-being.

Conclusions

Age, PS, survival time, and treatment status are important determinants of HRQL in patients with advanced cancer. Decision aids, open communication, and involvement of supportive care specialists may improve emotional and existential distress associated with changing or stopping cancer treatment.
Literatur
2.
Zurück zum Zitat Kaasa S, Loge JH (2003) Quality of life in palliative care: principles and practice. Palliat Med 17:11–20PubMedCrossRef Kaasa S, Loge JH (2003) Quality of life in palliative care: principles and practice. Palliat Med 17:11–20PubMedCrossRef
3.
Zurück zum Zitat Morrison RS, Meier DE (2004) Clinical practice. Palliative care. N Engl J Med 350:2582–2590PubMedCrossRef Morrison RS, Meier DE (2004) Clinical practice. Palliative care. N Engl J Med 350:2582–2590PubMedCrossRef
4.
Zurück zum Zitat Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA (2000) Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 284:2476–2482PubMedCrossRef Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA (2000) Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 284:2476–2482PubMedCrossRef
5.
Zurück zum Zitat Wilson KG, Chochinov HM, McPherson CJ, LeMay K, Allard P, Chary S et al (2007) Suffering with advanced cancer. J Clin Oncol 25:1691–1697PubMedCrossRef Wilson KG, Chochinov HM, McPherson CJ, LeMay K, Allard P, Chary S et al (2007) Suffering with advanced cancer. J Clin Oncol 25:1691–1697PubMedCrossRef
6.
Zurück zum Zitat Whitford HS, Olver IN, Peterson MJ (2008) Spirituality as a core domain in the assessment of quality of life in oncology. Psycho Oncology 17:1121–1128PubMedCrossRef Whitford HS, Olver IN, Peterson MJ (2008) Spirituality as a core domain in the assessment of quality of life in oncology. Psycho Oncology 17:1121–1128PubMedCrossRef
7.
Zurück zum Zitat Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M et al (2004) Normative data for functional assessment of cancer therapy—general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 43:153–160PubMedCrossRef Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M et al (2004) Normative data for functional assessment of cancer therapy—general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 43:153–160PubMedCrossRef
8.
Zurück zum Zitat Janda M, Disipio T, Hurst C, Cella D, Newman B (2009) The Queensland cancer risk study: general population norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Psycho Oncology 18:606–614PubMedCrossRef Janda M, Disipio T, Hurst C, Cella D, Newman B (2009) The Queensland cancer risk study: general population norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Psycho Oncology 18:606–614PubMedCrossRef
9.
Zurück zum Zitat Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire: the QLQ = C30 (+ 3). J Clin Oncol 16:1188–1196PubMed Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire: the QLQ = C30 (+ 3). J Clin Oncol 16:1188–1196PubMed
10.
Zurück zum Zitat Schwarz R, Hinz A (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37:1345–1351PubMedCrossRef Schwarz R, Hinz A (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37:1345–1351PubMedCrossRef
11.
Zurück zum Zitat Fossa SD, Hess SL, Dahl AA, Hjermstad MJ, Veenstra M (2007) Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis. Acta Oncol 46:452–461PubMedCrossRef Fossa SD, Hess SL, Dahl AA, Hjermstad MJ, Veenstra M (2007) Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis. Acta Oncol 46:452–461PubMedCrossRef
12.
Zurück zum Zitat Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 28:192–211PubMedCrossRef Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 28:192–211PubMedCrossRef
13.
Zurück zum Zitat Jordhoy MS, Fayers P, Loge JH, Saltnes T, Ahlner-Elmqvist M, Kaasa S (2001) Quality of life in advanced cancer patients: the impact of sociodemographic and medical characteristics. Br J Cancer 85:1478–1485PubMedCrossRef Jordhoy MS, Fayers P, Loge JH, Saltnes T, Ahlner-Elmqvist M, Kaasa S (2001) Quality of life in advanced cancer patients: the impact of sociodemographic and medical characteristics. Br J Cancer 85:1478–1485PubMedCrossRef
14.
Zurück zum Zitat Lundh HC, Seiger A, Furst CJ (2006) Quality of life in terminal care—with special reference to age, gender and marital status. Support Care Cancer 14:320–328CrossRef Lundh HC, Seiger A, Furst CJ (2006) Quality of life in terminal care—with special reference to age, gender and marital status. Support Care Cancer 14:320–328CrossRef
15.
Zurück zum Zitat Fisch MJ, Titzer ML, Kristeller JL, Shen J, Loehrer PJ, Jung SH et al (2003) Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being—a Hoosier oncology group study. J Clin Oncol 21:2754–2759PubMedCrossRef Fisch MJ, Titzer ML, Kristeller JL, Shen J, Loehrer PJ, Jung SH et al (2003) Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being—a Hoosier oncology group study. J Clin Oncol 21:2754–2759PubMedCrossRef
16.
Zurück zum Zitat Brady MJ, Peterman AH, Fitchett G, Mo M, Cella D (1999) A case for including spirituality in quality of life measurement in oncology. Psycho Oncology 8:417–428PubMedCrossRef Brady MJ, Peterman AH, Fitchett G, Mo M, Cella D (1999) A case for including spirituality in quality of life measurement in oncology. Psycho Oncology 8:417–428PubMedCrossRef
17.
Zurück zum Zitat Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H (1983) Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 140:734–739PubMed Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H (1983) Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 140:734–739PubMed
18.
Zurück zum Zitat Jordhoy MS, Fayers P, Loge JH, Ahlner-Elmqvist M, Kaasa S (2001) Quality of life in palliative cancer care: results from a cluster randomized trial. J Clin Oncol 19:3884–3894PubMed Jordhoy MS, Fayers P, Loge JH, Ahlner-Elmqvist M, Kaasa S (2001) Quality of life in palliative cancer care: results from a cluster randomized trial. J Clin Oncol 19:3884–3894PubMed
19.
Zurück zum Zitat Donner A, Piaggio G, Villar J, Pinol A, Al Mazrou Y, Ba'aqeel H et al (1998) Methodological considerations in the design of the WHO antenatal care randomized controlled trial. Paediatr Perinat Epidemiol 12(Suppl 2):59–74PubMedCrossRef Donner A, Piaggio G, Villar J, Pinol A, Al Mazrou Y, Ba'aqeel H et al (1998) Methodological considerations in the design of the WHO antenatal care randomized controlled trial. Paediatr Perinat Epidemiol 12(Suppl 2):59–74PubMedCrossRef
20.
Zurück zum Zitat Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O (1996) Randomized study of screening for colorectal cancer with faecal-occult blood test. Lancet 348:1467–1471PubMedCrossRef Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O (1996) Randomized study of screening for colorectal cancer with faecal-occult blood test. Lancet 348:1467–1471PubMedCrossRef
21.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
22.
Zurück zum Zitat Webster K, Cella D, Yost K (2003) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1(1):79PubMedCrossRef Webster K, Cella D, Yost K (2003) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1(1):79PubMedCrossRef
23.
Zurück zum Zitat Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561PubMedCrossRef Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561PubMedCrossRef
24.
Zurück zum Zitat Yost KJ, Eton DT (2005) Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 28:172–191PubMedCrossRef Yost KJ, Eton DT (2005) Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 28:172–191PubMedCrossRef
25.
Zurück zum Zitat Peterman AH, Fitchett G, Brady MJ, Hernandez L, Cella D (2002) Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy—Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med 24:49–58PubMedCrossRef Peterman AH, Fitchett G, Brady MJ, Hernandez L, Cella D (2002) Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy—Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med 24:49–58PubMedCrossRef
26.
Zurück zum Zitat Edmondson D, Park CL, Blank TO, Fenster JR, Mills MA (2008) Deconstructing spiritual well-being: existential well-being and HRQOL in cancer survivors. Psycho Oncology 17:161–169PubMedCrossRef Edmondson D, Park CL, Blank TO, Fenster JR, Mills MA (2008) Deconstructing spiritual well-being: existential well-being and HRQOL in cancer survivors. Psycho Oncology 17:161–169PubMedCrossRef
27.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
28.
30.
Zurück zum Zitat Feinstein AR (1996) Multivariable analysis: an introduction. Yale University Press, New Haven Feinstein AR (1996) Multivariable analysis: an introduction. Yale University Press, New Haven
31.
Zurück zum Zitat Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Using reference data on quality of life—the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 34:1381–1389PubMedCrossRef Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Using reference data on quality of life—the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 34:1381–1389PubMedCrossRef
32.
Zurück zum Zitat Exley C, Letherby G (2009) Managing a disrupted lifecourse: issues of identity and emotion work. Health 5:112–132 Exley C, Letherby G (2009) Managing a disrupted lifecourse: issues of identity and emotion work. Health 5:112–132
33.
Zurück zum Zitat Rauch PK, Muriel AC (2004) The importance of parenting concerns among patients with cancer. Crit Rev Oncol Hematol 49(1):37–42PubMedCrossRef Rauch PK, Muriel AC (2004) The importance of parenting concerns among patients with cancer. Crit Rev Oncol Hematol 49(1):37–42PubMedCrossRef
34.
Zurück zum Zitat Mor V, Allen S, Malin M (1994) The psychosocial impact of cancer on older versus younger patients and their families. Cancer 74:2118–2127PubMedCrossRef Mor V, Allen S, Malin M (1994) The psychosocial impact of cancer on older versus younger patients and their families. Cancer 74:2118–2127PubMedCrossRef
35.
Zurück zum Zitat Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P et al (2008) Predictive model for survival in patients with advanced cancer. J Clin Oncol 26:5863–5869PubMedCrossRef Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P et al (2008) Predictive model for survival in patients with advanced cancer. J Clin Oncol 26:5863–5869PubMedCrossRef
36.
Zurück zum Zitat Nelson CJ, Rosenfeld B, Breitbart W, Galietta M (2002) Spirituality, religion, and depression in the terminally ill. Psychosomatics 43:213–220PubMedCrossRef Nelson CJ, Rosenfeld B, Breitbart W, Galietta M (2002) Spirituality, religion, and depression in the terminally ill. Psychosomatics 43:213–220PubMedCrossRef
37.
Zurück zum Zitat Breitbart W (2002) Spirituality and meaning in supportive care: spirituality- and meaning-centered group psychotherapy interventions in advanced cancer. Support Care Cancer 10:272–280PubMedCrossRef Breitbart W (2002) Spirituality and meaning in supportive care: spirituality- and meaning-centered group psychotherapy interventions in advanced cancer. Support Care Cancer 10:272–280PubMedCrossRef
38.
Zurück zum Zitat Ando M, Morita T, Okamoto T, Ninosaka Y (2008) One-week short-term life review interview can improve spiritual well-being of terminally ill cancer patients. Psycho Oncology 17:885–890PubMedCrossRef Ando M, Morita T, Okamoto T, Ninosaka Y (2008) One-week short-term life review interview can improve spiritual well-being of terminally ill cancer patients. Psycho Oncology 17:885–890PubMedCrossRef
39.
Zurück zum Zitat Harrington SE, Smith TJ (2008) The role of chemotherapy at the end of life: "when is enough, enough?". JAMA 299:2667–2678PubMedCrossRef Harrington SE, Smith TJ (2008) The role of chemotherapy at the end of life: "when is enough, enough?". JAMA 299:2667–2678PubMedCrossRef
40.
Zurück zum Zitat Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18:893–903PubMed Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18:893–903PubMed
41.
Zurück zum Zitat De Leeuw JR, de Graeff A, Ros WJ, Blijham GH, Hordijk GJ, Winnubst JA (2001) Prediction of depression 6 months to 3 years after treatment of head and neck cancer. Head Neck 23:892–898PubMedCrossRef De Leeuw JR, de Graeff A, Ros WJ, Blijham GH, Hordijk GJ, Winnubst JA (2001) Prediction of depression 6 months to 3 years after treatment of head and neck cancer. Head Neck 23:892–898PubMedCrossRef
42.
Zurück zum Zitat Carlson LE, Angen M, Cullum J, Goodey E, Koopmans J, Lamont L et al (2004) High levels of untreated distress and fatigue in cancer patients. Br J Cancer 90:2297–2304PubMed Carlson LE, Angen M, Cullum J, Goodey E, Koopmans J, Lamont L et al (2004) High levels of untreated distress and fatigue in cancer patients. Br J Cancer 90:2297–2304PubMed
43.
Zurück zum Zitat Strong V, Waters R, Hibberd C, Rush R, Cargill A, Storey D et al (2007) Emotional distress in cancer patients: the Edinburgh Cancer Center symptom study. Br J Cancer 96:868–874PubMedCrossRef Strong V, Waters R, Hibberd C, Rush R, Cargill A, Storey D et al (2007) Emotional distress in cancer patients: the Edinburgh Cancer Center symptom study. Br J Cancer 96:868–874PubMedCrossRef
44.
Zurück zum Zitat Pascoe S, Edelman S, Kidman A (2000) Prevalence of psychological distress and use of support services by cancer patients at Sydney hospitals. Aust NZ J Psychiatry 34:785–791 Pascoe S, Edelman S, Kidman A (2000) Prevalence of psychological distress and use of support services by cancer patients at Sydney hospitals. Aust NZ J Psychiatry 34:785–791
45.
Zurück zum Zitat Aass N, Fossa SD, Dahl AA, Moe TJ (1997) Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur J Cancer 33:1597–1604PubMedCrossRef Aass N, Fossa SD, Dahl AA, Moe TJ (1997) Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur J Cancer 33:1597–1604PubMedCrossRef
46.
Zurück zum Zitat Husain AF, Stewart K, Arseneault R, Moineddin R, Cellarius V, Librach SL et al (2007) Women experience higher levels of fatigue than men at the end of life: a longitudinal home palliative care study. J Pain Symptom Manage 33:389–397PubMedCrossRef Husain AF, Stewart K, Arseneault R, Moineddin R, Cellarius V, Librach SL et al (2007) Women experience higher levels of fatigue than men at the end of life: a longitudinal home palliative care study. J Pain Symptom Manage 33:389–397PubMedCrossRef
47.
Zurück zum Zitat Akechi T, Kugaya A, Okamura H, Yamawaki S, Uchitomi Y (1999) Fatigue and its associated factors in ambulatory cancer patients: a preliminary study. J Pain Symptom Manage 17:42–48PubMedCrossRef Akechi T, Kugaya A, Okamura H, Yamawaki S, Uchitomi Y (1999) Fatigue and its associated factors in ambulatory cancer patients: a preliminary study. J Pain Symptom Manage 17:42–48PubMedCrossRef
48.
Zurück zum Zitat Redeker NS, Lev EL, Ruggiero J (2000) Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 14:275–290PubMed Redeker NS, Lev EL, Ruggiero J (2000) Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 14:275–290PubMed
49.
Zurück zum Zitat Pater JL, Zee B, Palmer M, Johnston D, Osoba D (1997) Fatigue in patients with cancer: results with national cancer institute of canada clinical trials group studies employing the EORTC QLQ-C30. Support Care Cancer 5:410–413PubMedCrossRef Pater JL, Zee B, Palmer M, Johnston D, Osoba D (1997) Fatigue in patients with cancer: results with national cancer institute of canada clinical trials group studies employing the EORTC QLQ-C30. Support Care Cancer 5:410–413PubMedCrossRef
50.
Zurück zum Zitat Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179PubMedCrossRef Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179PubMedCrossRef
51.
Zurück zum Zitat van Wijk CM, Kolk AM (1997) Sex differences in physical symptoms: the contribution of symptom perception theory. Soc Sci Med 45:231–246PubMedCrossRef van Wijk CM, Kolk AM (1997) Sex differences in physical symptoms: the contribution of symptom perception theory. Soc Sci Med 45:231–246PubMedCrossRef
52.
Zurück zum Zitat Barsky AJ, Peekna HM, Borus JF (2001) Somatic symptom reporting in women and men. J Gen Intern Med 16:266–275PubMedCrossRef Barsky AJ, Peekna HM, Borus JF (2001) Somatic symptom reporting in women and men. J Gen Intern Med 16:266–275PubMedCrossRef
53.
Zurück zum Zitat Cella D, Hahn EA, Dineen K (2002) Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11:207–221PubMedCrossRef Cella D, Hahn EA, Dineen K (2002) Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11:207–221PubMedCrossRef
54.
Zurück zum Zitat Wan GJ, Counte MA, Cella DF, Hernandez L, Deasy S, Shiomoto G (1999) An analysis of the impact of demographic, clinical, and social factors on health-related quality of life. Value Health 2:308–318PubMedCrossRef Wan GJ, Counte MA, Cella DF, Hernandez L, Deasy S, Shiomoto G (1999) An analysis of the impact of demographic, clinical, and social factors on health-related quality of life. Value Health 2:308–318PubMedCrossRef
55.
Zurück zum Zitat Jordhoy MS, Inger RG, Helbostad JL, Oldervoll L, Loge JH, Kaasa S (2007) Assessing physical functioning: a systematic review of quality of life measures developed for use in palliative care. Palliat Med 21:673–682PubMedCrossRef Jordhoy MS, Inger RG, Helbostad JL, Oldervoll L, Loge JH, Kaasa S (2007) Assessing physical functioning: a systematic review of quality of life measures developed for use in palliative care. Palliat Med 21:673–682PubMedCrossRef
Metadaten
Titel
Determinants of quality of life in patients with advanced cancer
verfasst von
Camilla Zimmermann
Debika Burman
Nadia Swami
Monika K. Krzyzanowska
Natasha Leighl
Malcolm Moore
Gary Rodin
Ian Tannock
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0866-1

Weitere Artikel der Ausgabe 5/2011

Supportive Care in Cancer 5/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.